ArticleAIDS (London, England)2009
Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV.
Article in AIDS (London, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 184 citations in OpenAlex.
- Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.Hepatology (Baltimore, Md.) · 2020Guideline
- Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men.Journal of the International AIDS Society · 2019Pooled it
- Comprehensive Evaluation of the Elecsys HCV Duo Immunoassay for Active Hepatitis C Detection: Insights From the DEPCDUO Study.Journal of medical virology · 2026Article
- HCV Core Antigen Diagnostic Performance for Acute/Recent HCV Infection in People With HIV-1: A Systematic Review and Meta-Analysis.Open forum infectious diseases · 2025Article
- Detection of anti-HCV antibodies in the clinical classification and epidemiological surveillance of HCV infection.Molecular biology reports · 2025Review
- Hepatitis C-Everything a Primary Care Physician Needs to Know About Diagnosis, Management, and Follow-Up.Journal of clinical medicine · 2025Review
- Review
- DNA-directed formation of plasmonic core-satellite nanostructures for quantification of hepatitis C viral RNA.Chemical science · 2024Article
- Opportunities for Enhanced Prevention and Control of Hepatitis C Through Improved Screening and Testing Efforts.The Journal of infectious diseases · 2024Article
- Acute hepatitis C virus infection: clinical update and remaining challenges.Clinical and molecular hepatology · 2023Review
- A new double-antigen sandwich test based on the light-initiated chemiluminescent assay for detecting anti-hepatitis C virus antibodies with high sensitivity and specificity.Frontiers in cellular and infection microbiology · 2023Article
- Three-Stage Pooled Plasma Hepatitis C Virus RNA Testing for the Identification of Acute HCV Infections in At-Risk Populations.Microbiology spectrum · 2022Article
- Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations.Microbiology spectrum · 2022Article
- Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.Journal of medical virology · 2022Article
- B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection.PLoS pathogens · 2022Article
- Paper microfluidic implementation of loop mediated isothermal amplification for early diagnosis of hepatitis C virus.Nature communications · 2021Article
- Detection of hepatitis C virus among HIV patients in Port Harcourt, Rivers State.African health sciences · 2021Article
- Article
- Review
- Evolving trends in the prevalence of hepatitis C virus antibody positivity among HIV-infected men in a community-based primary care setting.Journal of viral hepatitis · 2020Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveAn epidemic of acute hepatitis C virus (HCV) infection among HIV-positive men who have sex with men is occurring in urban centers in Western Europe and the United States. Early diagnosis and treatment of HCV results in improved sustained virological response rates. This study compared the sensitivity of reverse transcriptase PCR (RT-PCR) versus antibody screening for the diagnosis of early HCV infection in HIV-positive patients and estimated the length of time from HCV infection to the development of anti-HCV antibodies.
designPatients from the St Mary's Acute Hepatitis C Cohort (SMACC) were recruited retrospectively and prospectively between 2004 and 2008.
methodsArchived plasma samples, obtained at 1-3 monthly intervals for routine monitoring of HIV viral load were assayed retrospectively for HCV in order to assess the sensitivity of RT-PCR and enzyme-linked immunosorbent assay (ELISA).
results: Forty-three HIV-positive patients with early HCV infection were identified. The median CD4 cell count was 570 cells/microl. The median alanine transaminase at the time of the first positive HCV PCR was 65 IU/ml. At this time, 75% of patients had a negative HCV antibody test. Three months later, 37% of patients still had a negative result. After 9 months, 10% of patients had a negative test and 5% remained negative after 1 year. CONCLUSION/DISCUSSION: Delayed seroconversion in HIV-positive individuals with acute HCV may result in delayed diagnosis and treatment. Where there is a clinical suspicion of recent HCV infection, for example, elevated alanine transaminase levels, HIV-infected patients should be screened for HCV RNA by RT-PCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.